Core Insights - Cocrystal Pharma, Inc. presented favorable safety and tolerability data for its oral pan-viral inhibitor CDI-988 at the 2025 Military Health System Research Symposium, supporting its clinical development for norovirus prophylaxis and treatment [1][4] Group 1: Study Results - The Phase 1 study included single-ascending (SAD) and multiple-ascending (MAD) cohorts, with all doses (100 mg to 1200 mg) well tolerated [2][5] - Treatment-emergent adverse events were 28% in CDI-988 subjects compared to 40% in placebo subjects for SAD cohorts, and 53% versus 92% for MAD cohorts, with headache being the most common adverse event [2][3] - No severe treatment-emergent adverse events or clinically significant pathology results were reported [2][3] Group 2: Clinical Development and Market Need - CDI-988's development is particularly relevant for military settings where norovirus poses operational risks due to its high transmissibility [3][4] - The absence of approved treatments or vaccines for norovirus creates a critical unmet medical need, with CDI-988 targeting viral replication across all norovirus genogroups [4][6] - Cocrystal plans to initiate a Phase 1b challenge study with CDI-988 in norovirus-infected healthy subjects later this year [4][7] Group 3: Company Overview and Technology - Cocrystal Pharma is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics targeting various viruses, including noroviruses and coronaviruses [9] - CDI-988 was developed using Cocrystal's proprietary structure-based platform technology, designed as a broad-spectrum inhibitor targeting 3CL viral proteases [5][8] - Norovirus infections are estimated to cost society approximately $60 billion annually worldwide, highlighting the economic impact of this virus [6]